Shanghai GeneChem Co., Ltd.

Shanghai GeneChem Co., Ltd. (吉凯基因) was founded in 2002 and provides technical services and solutions covering the full process from basic research to drug discovery and development. Its business spans gene research, target discovery, target validation, drug development and drug evaluation, and it states a continuing commitment to enabling source innovation and robust drug development in the CGT field. Its service lines include multi-omics services, gene manipulation tools, target discovery and validation, early-stage drug development, pharmacology and efficacy evaluation, and cell therapy CDMO. The company describes itself as the Shanghai Tumor Drug Gene Target Engineering Technology Research Center and as one of Shanghai's first technology innovation centers — the Gene Therapy Technology Innovation Center. As of December 2022, it reported having completed more than 100,000 projects for over 300 cooperating units globally and having undertaken more than 40 national/local R&D projects.

Shanghai GeneChem Co., Ltd. was founded in 2002 and provides technical services and solutions covering the full process from basic research to drug discovery and development. Its business covers gene research, target discovery, target validation, drug development and drug evaluation, and it states a continuing commitment to enabling source innovation and robust drug development in the CGT field. The company describes itself as the Shanghai Tumor Drug Gene Target Engineering Technology Research Center and as one of Shanghai's first technology innovation centers — the Gene Therapy Technology Innovation Center. As of December 2022, it reported having completed more than 100,000 projects for over 300 cooperating units globally and having undertaken more than 40 national/local R&D projects. Its virus tool platform supplies viral vectors including Lenti, AdV, AAV and HSV, with more than 20,000 virus orders processed annually and more than 2,000 projects running simultaneously each day; its omics platform provides genomics, transcriptomics, proteomics, single-cell sequencing and bioinformatics analysis services; and its drug development and evaluation platform provides one-stop drug development and evaluation services to pharmaceutical companies globally. The company states that through more than 20 years of technology accumulation it has built distinctive strengths in research services and industrial services. In recent years it has participated in cooperation projects with biopharmaceutical companies including dozens of Chinese and US listed companies, and has helped multiple partners advance projects into the clinical stage. Its development history page lists milestones including: 2014 completion of A-round financing and recognition as a Shanghai patent work pilot enterprise; 2015 ISO9001:2008 certification and completion of B-round financing; 2016 establishment of the GeneChem Translational Medicine Research Institute; 2017 recognition as Shanghai Tumor Drug Gene Target Engineering Technology Research Center; 2018 recognition as a high-tech enterprise; 2020 designation as Shanghai Gene Therapy Technology Innovation Center; 2021 approval of two IND products and global cooperation deals with biopharmaceutical partners; and 2022 recognition as a national-level specialized and sophisticated 'little giant' enterprise.

Provides full-process technical services and solutions from basic research to drug discovery and development, with a stated vision of 'advancing translational medicine and empowering new drug creation' and a mission to build a bridge between basic and applied research together with clinicians.

• Multi-omics services

  Based on proteomics and high-throughput sequencing platforms, providing services such as 4D, DIA, TMT, PRM, phosphoproteomics and Olink proteomics detection, as well as single-cell sequencing and spatial omics.

• Gene manipulation tools

  Complete GMP production capability covering plasmids, viruses and cells, able to prepare a full series of gene manipulation tools from laboratory research to clinical treatment; tool categories include lentivirus, adenovirus, adeno-associated virus, plasmids, RNAi libraries, gene overexpression and gene regulation.

• Target discovery and validation

  Provides complete in vitro and in vivo functional validation services, including cytological experiments and animal disease models.

• Early-stage drug development

  Integrates clinical research databases, standardized basic research systems and mature drug development platforms to provide solutions covering the full process from basic research to drug discovery and development; includes cell therapy drugs, antibody drugs and small molecule drugs.

• Pharmacology and efficacy evaluation

  Provides in vitro and in vivo pharmacology and efficacy experiments, including gene expression validation, stable cell line construction, tumor cell functional experiments, antibody drug functional testing, immune cell experiments, tumor pharmacodynamics evaluation models and autoimmune inflammation evaluation models.

• Cell therapy CDMO

  GeneChem states it is one of the earliest companies in China to conduct CAR-T research and has years of CAR-T process development experience; it has an advanced R&D center, upstream and downstream process development laboratories, a production preparation base and a well-equipped quality control system. Services include GMP-like plasmids, GMP-like lentivirus and CAR-T/TCR-T cells.

1. 1吉凯基因genechem.com.cn
2. 2关于吉凯-吉凯基因genechem.com.cn
3. 3关于吉凯-吉凯基因genechem.com.cn
4. 4多组学服务-吉凯基因genechem.com.cn
5. 5Shanghai GeneChem Co., Ltd. (China)wikidata.org